The heart-study side effect that changed men’s health

A failed chest-pain trial in a small English town rewrote how clinics talk about sexual symptoms. The lesson was never “take this.” It was “ask a doctor, and do not improvise.”

In the late 1980s, a cardiovascular team at a research site in Sandwich, on the Kent coast, was trying to solve a familiar problem. Angina is chest pain from a heart that is not getting enough blood. The group was testing a compound meant to open blood vessels and ease that pain. On paper it was a heart project. Nothing about the brief mentioned sex.

The compound did not become the angina drug they had hoped for. It did not stay in the body long enough to be practical as a three-times-a-day chest medicine. In volunteer studies it also amplified the effect of nitrate medicines, the standard treatment for angina. Blood pressure could fall too far. That interaction alone was enough to shrink its prospects for the original job.

Then the side-effect reports started landing on the desks.

A trial with other plans

In 1992, during multiple-dose studies in healthy volunteers, some of the men reported something the protocol had not set out to measure. Erections. Not during the dosing window the team cared about for angina. Often later. Often awkwardly described. At first it was easy to file under noise. One scientist later recalled thinking that even if the effect was real, few people would want a medicine timed that way.

The reports did not stop. As the angina case weakened, the team ran small pilot studies in men with erectile dysfunction, the clinical name for impotence. Early tests were blunt by today’s standards: volunteers watched erotic films while a device recorded rigidity. The signal beat placebo. By 1997, a large clinical programme had followed. That spring, regulators in the United States approved the first oral treatment for erectile dysfunction. European approval followed that autumn.

What had failed as a heart drug had become a new category of medicine.

Why it changed the conversation

Before that approval, treatments for erectile dysfunction were easier to avoid than to discuss. Injections. Devices. A specialist appointment many men never booked. An oral tablet, taken in private, moved the subject from the margins of urology into ordinary primary care.

The culture moved faster than the caveats. Late-night comedy, newspaper columns and advertising treated a medical option as a personality. Clinics saw a rush of men who had lived with the symptom for years and had never raised it. That part was useful. Silence had been doing its own harm. The less useful part was the idea that a headline, a friend’s dose, or a product photographed on social media was a plan.

It was not. Erectile symptoms have many causes: blood flow, nerves, hormones, medicines, mood, sleep, alcohol, relationship strain. A tablet does not sort those. A clinician does.

The warning that should have travelled with the story

The same interaction that hurt the angina programme is still the one that matters most. Nitrate heart medicines, including nitroglycerin, do not mix with this class of treatment. Together they can drop blood pressure to a dangerous level. Anyone with chest pain, a stent, or a prescription for a nitrate needs that conversation before anything else.

Other effects showed up in the trials and in later use: headache, flushing, indigestion, a blocked nose, and in some people a blue tinge to vision. Most were transient. A few were not, including sudden vision or hearing loss, and an erection that does not settle. Those are reasons to stop and get urgent care, not reasons to adjust the dose at home.

Years later, the same line of research found a separate, narrower use in pulmonary arterial hypertension, a serious disease of the lung blood vessels. That is a specialist prescription. It is not a reason to borrow someone else’s tablets.

What a headline cannot tell you

A large observational study reported in 2025 linked treated erectile dysfunction with lower rates of death, heart attack and stroke in that dataset. Observational is the important word. Men who seek care differ from men who do not. The finding is a reason to take the symptom seriously as a vascular clue, not a reason to self-prescribe from an article.

Men35’s rule on this subject is the same as on aspirin, training, or any other health headline. Research can change what clinicians know without changing what you should do tomorrow morning.

Talk to a doctor or a pharmacist. Buy only through a licensed pharmacy, with a prescription, in a country where that supply is legal. Do not combine treatment with nitrate heart medicine. Do not start, stop, or switch because a page on the internet sounded confident.